Clinical Trial Update: Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bortezomib in KRAS-mutant non-small cell lung cancer in never smokers or KRAS G12D patients has been completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-07-23